Gilead Sciences, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 128   

Articles published

GILD 70.65 -0.59 (-0.83%)
price chart
Take Note Of The Hint Gilead Sciences Just Dropped
The stock suggests -- or did, anyway -- the company is about to implode. That's the market's subconscious way of saying it doesn't have much faith in the company's pipeline. IC took a pretty good, albeit abridged, look at the company's pipeline as well ...
Merck and Gilead among drug stocks buoyed by Trump's healthcare plans  Proactive Investors USA & Canada
How Gilead Sciences, Inc. (GILD) And Its Latest Technicals Are Playing Out  NY Stock News
Gilead: How Sweet It Is
Quick, quick, I have to get this article out the door. This happy feeling may be but a brief summer breeze. I need to share my joy which has been bottled up for so long.
Gilead: Is Sentiment Changing?
Gilead (NASDAQ:GILD) is up ~10% in the last week. Those bears are finally going to get what's coming to them for bashing management and saying this was a one-drug company. Gilead sure is proving them wrong now! Everyone aboard the hype train ...
Gilead: The Conundrum
Gilead for me is a stock for the true long term investor (at least 5 to 10 years+). Why? Because the profile this stock has at present definitely puts it into a position of a true long term value play.
Gilead Sciences, Inc.: The Bear Case From a Bull
I've remained positive about the company's long-term prospects. That being said, a reasonable bear case against Gilead comes pretty easily -- even from a bull like me.
Why to Keeping Eye on Gilead Sciences, Inc. (GILD), Texas Instruments ...  StockNewsJournal
Gilead Sciences, Inc. (NASDAQ:GILD) Trading Down – Insiders Are Selling  Highlight Press
Better Buy: Biogen Inc. vs. Gilead Sciences Inc.
The best thing going for Gilead Sciences right now is what made the biotech successful early on: its HIV franchise. Genvoya has been a huge success.
Gilead Sciences Is A Buy
Now to Gilead (NASDAQ:GILD). First, let me say that I know all the negatives facing this company. I know that its HCV (hepatitis C) franchise is experiencing intense competition and pricing pressure.
Gilead's Oncology Pipeline: An Assessment
Gilead Sciences (NASDAQ:GILD) lost its balm two years ago, when fears of a decline in its HCV franchise saw the stock plummeting from its $120s all time highs to the sad avatar that it is today of an once-mighty stock giant - $60 and change.
5 Answers to Questions Gilead Sciences' Investors Probably Have
Gilead's hepatitis C virus (HCV) franchise is flailing. Some are worried about cracks in the company's foundation -- its HIV franchise.
Gilead: A Strong Bet For Income
The company is not a value trap as it has too many growth triggers plus a pristine balance sheet. Furthermore the biotech sector will continue to grow.